Advertisement

TWi Biotechnology sees hints of success in anti-inflammatory approach to type 2 diabetes

13:20 EDT 7 Aug 2012 | SCRIP

The Taiwanese company TWi Biotechnology is having some success with an oral small-molecule IL-1beta inhibitor in the treatment of type 2 diabetes, Phase IIb data suggest. The product is the leading small molecule acting on this target being.....

Original Article: TWi Biotechnology sees hints of success in anti-inflammatory approach to type 2 diabetes

NEXT ARTICLE

More From BioPortfolio on "TWi Biotechnology sees hints of success in anti-inflammatory approach to type 2 diabetes"

Search BioPortfolio:
Advertisement
Advertisement